Factors Associated with Anticoagulation Adherence in Chinese Patients with Non-Valvular Atrial Fibrillation

Figures & data

Figure 1 Sample selection flowchart.

Table 1 Anticoagulation Adherence According to Morisky Medication Adherence Scale (MGL)

MGL Questions	Scoring	(%)
1. Do you ever forget to take your medicine?	No 1	78.80
	Yes 0	21.20
2. Are you careless at times about taking your medicine?	No 1	92.90
	Yes 0	7.10
3. Do you sometimes stop taking your medicine when you feel better?	No 1	90.60
	Yes 0	9.40
4. Sometimes, if you feel worse when you take medicine, do you stop taking it?	No 1	92.40
	Yes 0	7.60

Table 2 Sociodemographic and Clinical Characteristics of Patients (n=170)

Age		69.52±9.14
Gender, n(%)
Male	99	58.2
Female	71	41.8
Residence
Town	158	92.9
Country	12	7.1
Education level
Elementary school and lower	16	9.4
Junior high school	53	31.2
High school or technical secondary school	45	26.5
College degree and above	56	32.9
Marital status
Unmarried/Divorced/Widowed	26	15.3
Married	144	84.7
Employment status
Employed	15	8.8
Unemployed/Retired	155	91.2
Monthly income
<612€	23	13.5
≥612€	147	86.5
Insurance type
Urban employee/Resident basic medical insurance	154	90.6
New Rural Cooperative Medical Insurance	16	9.4
Duration of atrial fibrillation
<1 year	50	29.4
1~3 years	60	35.3
>3 years	60	35.3
Duration of anticoagulation therapy
<1 year	116	68.2
1~3 years	48	28.2
>3 years	6	3.6
Number of drugs
0~2	81	47.6
≥3	89	52.4
EHRA classification
I	49	28.8
II	97	57.1
III and IV	24	14.1
RFCA in the past
Yes	71	41.8
No	99	58.2
Bleeding
Yes	45	26.5
No	125	73.5
Types of complications
0	79	46.5
1~2	77	45.3
≥3	14	8.2
Types of atrial fibrillation
Paroxysmal atrial fibrillation	129	75.9
Persistent atrial fibrillation	41	24.1
CHA2DS2-VaSc score
<2	32	18.8
≥2	138	81.2

Table 3 Characteristics of the Patients According to Anticoagulation Adherence

	Low Adherence(n/%)	High Adherence(n/%)	P-value
Patients	50(29.4)	120(70.6)
Age	68.36±6.97	70.00±9.89	0.175
Gender			0.609
Male	31(62.0)	68(56.7)
Female	19(38.0)	52(43.3)
Residence			0.195
Town	44(88.0)	114(95.0)
Country	6(12.0)	6(5.0)
Education level			0.281
Elementary school and lower	7(14.0)	9(7.5)
Junior high school	18(36.0)	35(29.1)
High school or technical secondary school	13(26.0)	32(26.7)
College degree and above	12(24.0)	44(36.7)
Marital status			0.441
Unmarried/Divorced/Widowed	6(12.0)	20(16.7)
Married	44(88.0)	100(83.3)
Employment status			0.807
Employed	4(8.0)	11(9.2)
Unemployed/Retired	46(92.0)	109(90.8)
Monthly income			0.001
<612€	14(28.0)	9(7.5)
≥612€	36(82.0)	111(92.5)
Insurance type			0.301
Urban employee/Resident basic medical insurance	7(14.0)	9(7.5)
New Rural Cooperative Medical Insurance	43(86.0)	111(92.5)
Duration of atrial fibrillation			0.892
<1 year	14(28.0)	36(30.0)
1~3 years	17(34.0)	43(35.8)
>3 years	19(38.0)	41(34.2)
Duration of anticoagulation therapy			0.515
<1 year	37(74.0)	79(65.8)
1~3 years	12(24.0)	36(30.0)
>3 years	1(2.0)	5(4.2)
Number of drugs			0.006
0~2	32(64.0)	49(40.8)
≥3	18(36.0)	71(59.2)
EHRA classification	Low adherence	High adherence	0.261
I	10(20.0)	39(32.5)
II	32(64.0)	65(54.2)
III and IV	8(16.0)	16(13.3)
RFCA in the past			0.968
Yes	21(42.0)	50(41.7)
No	29(58.0)	70(58.3)
Bleeding			0.151
Yes	17(34.0)	28(23.3)
No	33(66.0)	92(76.7)
Types of complication			0.047
0	16(32.0)	63(52.5)
1~2	29(58.0)	48(40.0)
≥3	5(10.0)	9(7.5)
Types of atrial fibrillation			0.418
Paroxysmal atrial fibrillation	40(80.0)	89(74.2)
Persistent atrial fibrillation	10(20.0)	31(25.8)
CHA2DS2-VaSc score			0.859
<2	9(18.0)	23(19.2)
≥2	41(82.0)	97(80.8)
Self-efficacy score (Mean±SD)			<0.001
	32.13±1.50	36.48±3.83

Table 4 Logistic Regression: Factors Influencing NOACs Adherence

Variables	Low Adherence	High Adherence	Odds Ratio (95% CI)	P-value
Monthly income, n (%)
<612€	14 (73.9)	9 (27.1)	1	-
≥612€	36 (24.5)	111 (75.5)	7.87[2.68–23.11]	0.001
Number of drugs, n (%)
0~2	32(39.5)	49(60.5)	1	-
≥3	18(18.2)	71(81.8)	3.51[1.57–8.01]	0.002
Types of complication n (%)
0	16(20.3)	63(79.7)	8.00[1.90–33.71]	0.005
1~2	29(37.7)	48(62.3)	2.33[0.63–8.64]	0.207
≥3	5(35.7)	9(64.3)	1	-
Self-efficacy score	32.13±1.50	36.48±3.83	1.42[1.15–1.74]	0.001